Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Tumor-destroying sound waves receive FDA approval for liver
View:
Post by kijiji on Oct 17, 2023 5:22pm

Tumor-destroying sound waves receive FDA approval for liver

The U.S. Food and Drug Administration has approved the use of sound waves to break down tumors—a technique called histotripsy—in humans for liver treatment.
 
Pioneered at the University of Michigan, histotripsy offers a promising alternative to cancer treatments such as surgery, radiation and chemotherapy, which often have significant side effects. Today, FDA officials awarded clearance to HistoSonics, a company co-founded in 2009 by U-M engineers and doctors for the use of histotripsy to destroy targeted liver tissue.
 
A human trial underway since 2021 at the U-M Rogel Cancer Center and other locations has treated patients with primary and metastatic liver tumors via histotripsy, demonstrating the technology’s ability to meet the testing’s primary effectiveness and safety targets.

“Histotripsy is an exciting new technology that, although it is in early stages of clinical use, may provide a noninvasive treatment option for patients with liver cancer. Hopefully it can be combined with systemic therapies for a synergistic therapeutic effect,” said Mishal Mendiratta-Lala, professor of radiology with Michigan Medicine and principal investigator on the trial at U-M.
 
HistoSonics can now market and sell its histotripsy delivery platform, called Edison, to hospitals and medical professionals for use in liver treatments. The company is headquartered in Minneapolis, while its advanced research and development is located in Ann Arbor.
 
Histotripsy works by using targeted ultrasound waves to form microbubbles within the tumor. The forces created as those bubbles form and collapse cause the mass to break apart, killing tumor cells and leaving the debris to be cleaned up by the immune system.

What that could mean for patients is treatment without the physical toll of radiation or chemotherapy, fewer concerns with drug compatibility, far shorter recovery times than with surgery and less treatment discomfort.
 
This is possible because it is much easier to ensure that histotripsy treatments are hitting the tumor, and not healthy tissue, compared to radiation or invasive procedures. Histotripsy relies on focusing acoustic waves of high energy ultrasound to concentrate the energy enough to form bubbles, and the Edison machine can make sure that region is confined to the tumor. In contrast, radiation affects everything in its path through the body.
 
In addition, the histotripsy system has onboard diagnostic ultrasound imaging, the kind used to see babies in the womb. It is used to plan and observe the treatment in real time. Physicians have a live view of the “bubble cloud” and how tissue is responding to the therapy.

And histotripsy’s potential benefits go beyond tumor destruction. In the last year, a pair of preclinical studies in rodents suggest that in the clean-up process, the immune system learns how to identify cancer cells as threats. This can enable the body to continue fighting the initial tumor and help activate a natural immune response to the cancer.
 
In the first study, even after destroying only 50% to 75% of the liver tumor volume by histotripsy, the rats’ immune systems were able to clear away the rest, with no evidence of recurrence or metastases in more than 80% of animals.
 
Earlier this year, a second study showed that histotripsy breaks down the cancer cell wall’s “cloak”—revealing proteins that the immune system can use to identify threats, known as antigens. These antigens are removed during surgery or destroyed during chemotherapy and radiation. By instead destroying a cancer cell’s outer wall, histotripsy lays bare the tumor antigens for the immune system to identify and use for targeted attacks on other cancer cells.

“We want to leverage histotripsy’s immuno stimulation effects and hopefully combine them with immunotherapy or drug delivery,” said Zhen Xu, U-M professor of biomedical engineering, an inventor of the histotripsy approach and a co-founder of HistoSonics.
 
“That will move histotripsy from a local therapy into one that can treat tumors globally all over the body and eventually into a cure. In terms of the cancer treatment, that will be the next step, and I feel very excited about the potential.”
 
Xu and the University of Michigan have a financial interest in HistoSonics. The company was formed with support from U-M’s Coulter Translational Research Program and Innovation Partnerships, U-M’s hub for research commercialization.
Comment by Eoganacht on Oct 17, 2023 6:15pm
Speaking of which, Dr. Mandel and Roger Dumoulin-White applied for a sonodynamic therapy patent in 2021. SONODYNAMIC THERAPY USING SONODYNAMICALLY ACTIVATED COORDINATION COMPLEXES OF TRANSITION METALS AS SENSITIZING AGENTS  
Comment by Pandora on Oct 17, 2023 7:21pm
That patent has been given a Notice of Allowance (July 19, 2023) i.e. 'approval' -- and the fee was requested to trigger the issue of the patent. Payment of the fee has been acknowledged (Sept. 21, 2023) so it should be a short time to have an issue date announced. The patent process is slow but it usually does not take that long from Notice of Allowance to 'Issue' -- in my ...more  
Comment by Pandora on Oct 17, 2023 7:53pm
I may be ahead of myself on that last post. Understanding of the language of the documents can be a struggle at times :-)) I think in going back to an approved document (as an example) that item "Issue Fee Payment" is actually the USPTO saying to the Company that they have been issued a request for fee payment ($480). After the Company pays the money (by card or whatever) the item for ...more  
Comment by FGPstock on Oct 18, 2023 12:41am
  pamdoras a rock star when it comes to patemts. Surprising Tlt never mentioned much about liver 
Comment by Pandora on Oct 18, 2023 4:30pm
Back to the Sonodynamic Patent and hopefully a little more clarification on status. (i.e. not a rock star performance). What I showed the other day was the "Documents" register and I did not show the accompanying "Transactions" register. Below is the Transactions register and in fact it shows the Fee as being paid on Sept. 20th and "Ready for Issue" and " ...more  
Comment by O12009 on Oct 18, 2023 4:42pm
Great job! 
Comment by Pandora on Oct 18, 2023 5:01pm
Also keep in mind the "Cannabinoid" patent has been cleared through the FDC process and was given Patent # 11793818 and an issue date of October 24, 2023. (next week) I am also tracking a 3rd one which was rejected by the examiner on September 18th. I will post updates as it moves through. This is the one that has conflicts with prior art on previous submissions by "Mandel" ...more  
Comment by Eoganacht on Oct 17, 2023 8:25pm
Thanks for the update, Pandora 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250